Efficacy and safety of dapagliflozin by baseline glycemic status: a prespecified analysis from the DAPA-CKD trial
Open accessAbstract
OBJECTIVE: The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status. RESEARCH DESIGN AND METHODS: We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2, and urinary albumin-to-creatinine ratio 200–5,000 mg/g. The primary composite end point was sustained eGFR decline ≥50%, end-stage kidney disease, or kidney or cardiovascular death. RESULTS: Of 4,304 participants, 738 had normoglycemia, 660 had prediabetes, and 2,906 had type 2 diabetes. The effect of dapagliflozin on the primary outcome was consistent (P for interaction = 0.19) in normoglycemia (hazard ratio [HR] 0.62 [95% CI 0.39, 1.01]), prediabetes (HR 0.37 [0.21, 0.66]), and type 2 diabetes (HR 0.64 [0.52, 0.79]). We found no evidence for effect modification on any outcome. Adverse events were similar, with no major hypoglycemia or ketoacidosis in participants with normoglycemia or prediabetes. CONCLUSIONS: Dapagliflozin safely reduced kidney and cardiovascular events independent of baseline glycemic status.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Multiple SGLT2i trials included subsets of participants without diabetes, who appear to have derived similar benefits as those with T2D.
“Multiple SGLT2i trials included subsets of participants without diabetes, who appear to have derived similar benefits as those with T2D, 8,14,18”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140 · see citing works
Self-citationDapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · see citing works
Self-citationAnker, S. D., Butler, J., Filippatos, G., Khan, M. S., Marx, N., Lam, C. S. P., Schnaidt, S., Ofstad, A. P., Brueckmann, M., Jamal, W., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051824 · Cited by 352 · see citing works
Packer, M. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2020.04.016 · Cited by 215 · see citing works
Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes
Li, J., Neal, B., Perkovic, V., de Zeeuw, D., Neuen, B. L., Arnott, C., Simpson, R., Oh, R., Mahaffey, K. W., & Heerspink, H. J. L. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.051 · Cited by 130 · see citing works
Self-citationCannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044359 · Cited by 117 · see citing works
Self-citationEffects of Dapagliflozin on Volume Status When Added to Renin–Angiotensin System Inhibitors
Eickhoff, M. K., Dekkers, C. C. J., Kramers, B. J., Laverman, G. D., Frimodt‐Møller, M., Jørgensen, N. R., Faber, J. O., Danser, A. H. J., Gansevoort, R. T., Rossing, P. R., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060779 · Cited by 93 · see citing works
Self-citationFærch, K., Blond, M. B., Bruhn, L., Amadid, H., Vistisen, D., Clemmensen, K. K. B., Vainø, C. T. R., PEDERSEN, C. H., Tvermosegaard, M., Dejgaard, T. F., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05306-1 · Cited by 60 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507 · see citing works
Rossing, P., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2022) · Kidney International · doi:10.1016/j.kint.2022.06.013 · Cited by 274 · see citing works
Self-citationKidney and heart failure outcomes associated with SGLT2 inhibitor use
der Beek, A. B. V. D. A., de Boer, R. A., & Heerspink, H. J. L. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00535-6 · Cited by 183 · see citing works
Self-citationCombination therapy for kidney disease in people with diabetes mellitus
van Raalte, D. H., Bjornstad, P., Cherney, D. Z. I., de Boer, I. H., Fioretto, P., Gordin, D., Persson, F., Rosas, S. E., Rossing, P., Schaub, J. A., et al. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00827-z · Cited by 127 · see citing works
Self-citationApplications of SGLT2 inhibitors beyond glycaemic control
O’Hara, D. V., Lam, C. S. P., McMurray, J. J. V., Yi, T. W., HOCKING, S. L., Dawson, J., Raichand, S., Januszewski, A. S., & Jardine, M. (2024) · Nature Reviews Nephrology · doi:10.1038/s41581-024-00836-y · Cited by 111 · see citing works
Self-citationHeerspink, H. J. L., Apperloo, E., Davies, M., Dicker, D., Kandler, K., Rosenstock, J., Sørrig, R., Lawson, J., Zeuthen, N., & Cherney, D. (2023) · Diabetes Care · doi:10.2337/dc22-1889 · Cited by 98 · see citing works
Self-citationZhang, Y., Jiang, L., Wang, J., Wang, T., Chien, C., Huang, W., Fu, X., Xiao, Y., Fu, Q., Wang, S., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01676-5 · Cited by 96 · see citing works
The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge
Borg, R., Carlson, N., Søndergaard, J., & Persson, F. (2023) · International Journal of Nephrology · doi:10.1155/2023/9609266 · Cited by 106 · see citing works
Self-citationWaijer, S. W., Vart, P., Cherney, D. Z. I., Chertow, G. M., Jongs, N., Langkilde, A. M., Mann, J. F. E., Mosenzon, O., McMurray, J. J. V., Rossing, P. R., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05694-6 · Cited by 70 · see citing works
Self-citationBae, J. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0220 · Cited by 72 · see citing works
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD
Mayne, K. J., Staplin, N., Keane, D. F., Wanner, C., Brenner, S., Cejka, V., Stegbauer, J., Judge, P. K., Preiss, D., Emberson, J., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000271 · Cited by 58 · see citing works
Diabetes and Its Cardiovascular Complications: Comprehensive Network and Systematic Analyses
Wu, H., Norton, V., Cui, K., Zhu, B., Bhattacharjee, S., Lu, Y. W., Wang, B., Shan, D., Wong, S., Dong, Y., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.841928 · Cited by 54 · see citing works
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · Diabetes Care · doi:10.2337/dc22-0772 · Cited by 44 · see citing works
Dapagliflozin delays renal fibrosis in diabetic kidney disease by inhibiting YAP/TAZ activation.
Feng, L., Chen, Y., Li, N., Yang, X.-J., Zhou, L., Li, H.-R., Wang, T.-T., Xie, M., & Liu, H.-B. (2023) · Life Science · doi:10.1016/j.lfs.2023.121671 · Cited by 36 · see citing works
Sen, T., Scholtes, R. A., Greasley, P. J., Cherney, D. Z. I., Dekkers, C. C. J., Vervloet, M. G., Danser, A. H. J., Barbour, S. J., Karlsson, C., Hammarstedt, A., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14729 · Cited by 39 · see citing works
Self-citationSGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
Thomas, M. C., Neuen, B. L., Twigg, S. M., Cooper, M. E., & Badve, S. V. (2023) · Endocrine Connections · doi:10.1530/ec-23-0005 · Cited by 40 · see citing works
Aroda, V. R., & Eckel, R. H. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14830 · Cited by 38 · see citing works
Zeng, J., Huang, H., Zhang, Y., Lv, X., Cheng, J., Zou, S., Han, Y., Wang, S., Gong, L., & Peng, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1095487 · Cited by 35 · see citing works
Yang, S., Liu, Y., Zhang, S., Wu, F., Liu, D., Wu, Q., Zheng, H., Fan, P., & Su, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1145587 · Cited by 37 · see citing works
Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD
Sridhar, V. S., Bhatt, D. L., Odutayo, A., Szarek, M. J., Davies, M. J., Banks, P. L., Pitt, B., Steg, P. G., & Cherney, D. Z. I. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000414 · Cited by 36 · see citing works
Teo, Y. N., Ting, A. Z. H., Teo, Y. H., Chong, E. Y., Tan, J. T. A., Syn, N. L. X., Chia, A. Z. Q., Ong, H. T., Cheong, A. J. Y., Li, T. Y., et al. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-022-00528-7 · Cited by 35 · see citing works
Deschaine, B., Verma, S., & Rayatzadeh, H. (2022) · Cardiac failure review · doi:10.15420/cfr.2022.11 · Cited by 33 · see citing works
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 35 · see citing works
Yang, S., Zhao, L., Mi, Y., & He, W. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14801 · Cited by 32 · see citing works
Effect of SGLT2 inhibitors on the proteinuria reduction in patients with IgA nephropathy
Dong, Y., Shi, S., Liu, L., Zhou, X., Lv, J., & Zhang, H. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1242241 · Cited by 28 · see citing works
Lim, J., Kwon, S., Seo, Y. J., Kim, Y., Kwon, H., Kim, D. K., Lee, H., Kim, Y.-L., Kim, C., Park, S.-H., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.05.022 · Cited by 25 · see citing works
Gohda, T., & Murakoshi, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232213749 · Cited by 25 · see citing works
Lv, X., Wang, J., Zhang, L., Shao, X., Lin, Y., Liu, H., Ma, G., Li, J., Zhou, S., & Pei, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.993869 · Cited by 25 · see citing works
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 21 · see citing works
Reyes-Farias, C. I., Reategui-Diaz, M., Romani-Romani, F., & Prokop, L. (2023) · PLOS ONE · doi:10.1371/journal.pone.0295059 · Cited by 20 · see citing works
Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria
Heerspink, H. J., Provenzano, M., Vart, P., Jongs, N., Correa‐Rotter, R., Rossing, P. R., Mark, P. B., Pecoits‐Filho, R., McMurray, J. J. V., Langkilde, A. M., et al. (2024) · American Heart Journal · doi:10.1016/j.ahj.2024.02.006 · Cited by 23 · see citing works
Self-citationBeyond SGLT2: proximal tubule transporters as potential drug targets for chronic kidney disease
Wagner, C. A. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae211 · Cited by 19 · see citing works
Dapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 19 · see citing works
Beernink, J. M., Persson, F., Jongs, N., Laverman, G. D., Chertow, G. M., McMurray, J. J. V., Langkilde, A. M., Correa-Rotter, R., Rossing, P., Sjöström, C. D., et al. (2023) · Diabetes Care · doi:10.2337/dc22-1514 · Cited by 18 · see citing works
Self-citationNgoc, N. B., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15201 · Cited by 17 · see citing works
Yi, Y., Kwon, E., Yun, G., Park, S., Jeong, J. C., Na, K. Y., Chin, H. J., Yoo, S., Kim, S., Oh, T. J., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-52078-4 · Cited by 17 · see citing works
Baseline, Early Changes, and Residual Albuminuria
van Mil, D., Vart, P., Chertow, G. M., Gansevoort, R. T., Rossing, P. R., Toto, R. D., Correa-Rotter, R., Langkilde, A. M., Sjöström, C. D., Wheeler, D. C., et al. (2024) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000550 · Cited by 17 · see citing works
Self-citationÖzgümüş, T., Sulaieva, O., Jessen, L. E., Jain, R., Falhammar, H., Nyström, T., Catrina, S., Jörneskog, G., Groop, L., Eliasson, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00183-z · Cited by 13 · see citing works
Albarrán, O. G., Morales, C., Pérez-Maraver, M., Aparicio-Sánchez, J. J., & Simó, R. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01276-2 · Cited by 13 · see citing works
Tye, S. C., de Vries, S. T., Wanner, C., Denig, P., & Heerspink, H. J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.786706 · Cited by 11 · see citing works
Self-citationZhang, Y., Wang, J., Jiang, L., Wang, T., Li, Z., Fu, X., Huang, W., Xiao, Y., Wang, S., & Zhao, J. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00929-3 · Cited by 11 · see citing works
Lv, J., Guo, L., Wang, R., & Chen, J. (2023) · Kidney Diseases · doi:10.1159/000530395 · Cited by 13 · see citing works
Scheen, A. J. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101508 · Cited by 10 · see citing works
Rossing, P. R., Caramori, M. L., Chan, J. C. N., & Al., E. (2023) · KIDNEYS · doi:10.22141/2307-1257.11.4.2022.386 · Cited by 10 · see citing works
Self-citationBeernink, J. M., Jongs, N., Mosterd, C. M., Scholtes, R. A., Caldwell‐McGee, A., Casillas, D. I., Driscoll, L. M., Greasley, P. J., Karlsson, C., Hammarstedt, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16478 · Cited by 7 · see citing works
Self-citationCardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
Charytan, D. M., Mahaffey, K. W., Jardine, M., Cannon, C. P., Neal, B. C., Heerspink, H. J. L., Agarwal, R., Bakris, G. L., de Zeeuw, D., Levin, A., et al. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003270 · Cited by 10 · see citing works
Self-citationFelix, N. S., Gauza, M. D. M., Teixeira, L., Guisso, M. E. S., Nogueira, A., Dagostin, C. S., Godoi, A., Ribeiro, S. A. G., Duque, J. C., Moura-Neto, J. A., et al. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2023.0241 · Cited by 7 · see citing works
Position of SGLT2i in prediabetes: A systematic review of literature
Biswas, K., Reddy, V. B., Seshadri, K., Kapoor, N., Dharmalingam, M., & Anthuvan, T. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_238_24 · Cited by 5 · see citing works
Prediabetes and CKD: Does a causal relationship exist
Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología · doi:10.1016/j.nefro.2024.06.008 · Cited by 5 · see citing works
SGLT2 Inhibitors and Kidney Diseases: A Clinical Perspective
Theofilis, P., & Kalaitzidis, R. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867330666221227091943 · Cited by 5 · see citing works
Effects of Dapagliflozin in Patients with Membranous Nephropathy
Chertow, G. M., Heerspink, H. J. L., Mark, P. B., Dwyer, J. P., Nowicki, M. P., Wheeler, D. C., Correa‐Rotter, R., Rossing, P. R., Toto, R. D., Langkilde, A. M., et al. (2024) · Glomerular Diseases · doi:10.1159/000539770 · Cited by 4 · see citing works
Self-citationSridhar, V. S., Kugathasan, L., Lytvyn, Y., Deng, Y., Liu, H., Lovblom, L. E., TSE, J. M., Nardone, M., Floras, J. S., Osuntokun, T., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25955 · Cited by 3 · see citing works
Self-citationRossing, P. R., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K. K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., et al. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2481-2004 · Cited by 3 · see citing works
Self-citationGoldenberg, R. (2021) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.10.001 · Cited by 3 · see citing works
Effect of finerenone on proteinuria reduction in IgA nephropathy
Yu, G., Wang, M., Zhang, X., Tao, J., Zhao, J., Liu, S., Zhou, S., Zhou, J., Ren, P., Cheng, J., et al. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2588501 · Cited by 2 · see citing works
Dapagliflozin for Chronic Kidney Disease
Khangura, S. D., & Severn, M. (2022) · Canadian Journal of Health Technologies · doi:10.51731/cjht.2022.354 · Cited by 1 · see citing works
Prediabetes and CKD: Does a causal relationship exist
Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2024.11.005 · Cited by 1 · see citing works
Finerenone in SGLT-2 Inhibitors Era: Current Positioning in Diabetic Kidney Disease
Singh, A. K., Singh, R., Shah, V. N., & Misra, A. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0041 · Cited by 1 · see citing works
Chiang, H.-Y., Li, L., Hsu, C., Lin, C., Chan, Y., Wang, C., & Chen, C. (2023) · Pharmaceuticals · doi:10.3390/ph16081087 · Cited by 1 · see citing works
Elkeraie, A. F., Al-Ghamdi, S., Abu‐Alfa, A. K., Al-Otaibi, T., Alsaedi, A. J., AlSuwaida, A., Arıcı, M., Ecder, T., Ghnaimat, M. A., Hafez, M., et al. (2024) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s430532 · Cited by 1 · see citing works
Modern Approaches to Treatment of Chronic Heart Failure in Patients with Type 2 Diabetes Mellitus
Gorb, Y. G., Serik, S. A., Tkachenko, O. V., & Ryabukha, V. V. (2022) · Ukraïnsʹkij žurnal medicini bìologìï ta sportu · doi:10.26693/jmbs07.01.014 · Cited by 1 · see citing works
Új terápiás stratégiák a diabéteszes vesebetegség kezelésében
Balogh, Z. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.25
Dapagliflozin überzeugt erneut
Krome, S. (2021) · Diabetologie und Stoffwechsel · doi:10.1055/a-1647-6523
Шамхалова, М. Ш., Sukhareva, O. Y., & Shestakova, M. V. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.10.201883
Improving kidney protection in patients with type 2 diabetes
der Beek, A. B. V. D. A. (2023) · doi:10.33612/diss.637600695
Rodriguez‐Valadez, J. M., Tahsin, M., Fleischmann, K. E., Masharani, U. B., Yeboah, J., Park, M., Li, L., Weber, E. S., Li, Y., Berkalieva, A., et al. (2023) · doi:10.2337/figshare.22186279.v1
Results of the DAPA-CKD trial and their impact on clinical practice
Bilchenko, O. V. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.4.2023.1290
Role of newer anti-diabetes drugs in prediabetes: A systematic review
Singh, A. K., & Singh, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-85732-1.00037-2
Nandave, M. (2024) · Springer eBooks · doi:10.1007/978-981-97-7568-2_7
Gosmanov, A. R. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf690
Qiuyu, B., Xian, W., & Jinhu, C. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1619_25
Lv, X., Lu, C., Liu, H., Wei, H., Xu, J., He, D., Yan, C., & Shao, W. (2026) · American Journal of Nephrology · doi:10.1159/000550928
Sodium Glucose Transport Protein-2 (SGLT-2) Inhibitors
Jung, D., & Ali, O. (2026) · Springer eBooks · doi:10.1007/978-3-032-12626-9_8
Effect of dapagliflozin in liver transplant recipients with chronic kidney disease
Graf, C., Zeuzem, N., Bauschen, A., Allgeier, J., Denk, G., Paulig, C., Kemmner, S., Guba, M. O., & Lange, C. M. (2026) · Journal of Liver Transplantation · doi:10.1016/j.liver.2026.100356
McGill, J. B., Green, J., Heerspink, H. J. L., Mann, J. F. E., Mottl, A. K., Rosenstock, J., Rossing, P. R., Vaduganathan, M., Nangaku, M., BRINKER, M. D., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70949
Self-citationMetabolism in PTEN hamartoma tumour syndrome
Ambery, P., Bågenholm, R., Pepper, T., Barton, C. M., Whitehead, M. A., Rodriguez, L. H., & Greasley, P. J. (2026) · Metabologia · doi:10.1007/s44357-026-00008-4
El-Domiaty, H. F., El-Dessouky, A., & Salem, H. R. (2026) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-026-05915-4
- Authors
- Persson, F., Rossing, P., Vart, P., Chertow, G. M., Hou, F. F., Jongs, N., McMurray, J. J. V., Correa-Rotter, R., Bajaj, H. S., Stefansson, B. V., Toto, R. D., Langkilde, A. M., Wheeler, D. C., & Heerspink, H. J. L.
- Affiliations
- Steno Diabetes Center Copenhagen (DK)
- University of Copenhagen (DK)
- University Medical Center Groningen (NL)
- Stanford Medicine (US)
- Nanfang Hospital (CN)
- University of Glasgow (GB)
- National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City, Mexico
- LMC Diabetes & Endocrinology (Canada) (CA)
- Late-stage Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden
- The University of Texas Southwestern Medical Center (US)
- AstraZeneca (Sweden) (SE)
- The George Institute for Global Health (AU)
- Corresponding author
- Persson, Frederik
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-06-28
- Volume
- 44
- Issue
- 8
- Pages
- 1894-1897
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8385469
- OpenAlex
- W3174397236
- Cited by
- 78
- References
- 8
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 17 · 2023: 21 · 2022: 23 · 2021: 3
- FWCI
- 10.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, other-oa)
- PubMed Central (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alnylam Pharmaceuticals
- Cytokinetics
- ReCor Medical
- Quest Diagnostics
- Kowa Company
- Steno Diabetes Center Copenhagen (SDCC 3.A Complications)
- Satellite Healthcare
- Angion
- Kidney Research UK
- University of Glasgow
- Novo Nordisk
- Astellas Pharma
- Servier
- Akebia Therapeutics
- Defense Acquisition Program Administration
- Relypsa
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- dapagliflozin, chronic kidney disease, prediabetes, type 2 diabetes, normoglycemia, effect modification, renal outcomes, cardiovascular outcomes, SGLT2 inhibitors, DAPA-CKD trial, hypoglycemia, ketoacidosis
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
